Esperion Therapeutics, Inc. Cash Flow Statement
ESPR / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
Esperion Therapeutics, Inc. used $13M in operating cash flow and negative free cash flow of $13M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -1.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.6%
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$22.7M | -$51.7M | -$209.2M | -$233.7M | -$269.1M | -$143.6M | -$97.2M | -$201.8M | -$167.0M | -$75.0M | -$49.8M | -$36.4M | -$26.1M | -$11.7M | -$10.8M |
| Depreciation & Amortization | $105.0K | $63.0K | $164.0K | $500.0K | - | - | - | $265.0K | $258.0K | $252.0K | $236.0K | $160.0K | $71.0K | $139.0K | $178.5K |
| Operating Cash Flow | -$13.1M | -$23.7M | -$135.5M | -$174.8M | -$263.8M | -$85.2M | -$70.3M | -$148.6M | -$131.3M | -$47.7M | -$38.2M | -$32.0M | -$18.1M | -$10.8M | -$9.1M |
| Capital Expenditures | $0 | $317.0K | $0 | $0 | $0 | $869.0K | $953.0K | $151.0K | $19.0K | $94.0K | $325.0K | $873.0K | $31.0K | $7.0K | $33.6K |
| Free Cash Flow | -$13.1M | -$24.0M | -$135.5M | -$174.8M | -$263.8M | -$86.0M | -$71.3M | -$148.8M | -$131.3M | -$47.8M | -$38.5M | -$32.9M | -$18.1M | -$10.8M | -$9.1M |
| Share Buybacks | - | - | - | - | $0 | $55.0M | $0 | $0 | - | - | - | - | - | - | - |
| FCF Margin | -3.3% | -7.2% | -116.5% | -231.6% | -336.3% | -37.8% | -48.0% | - | - | - | - | - | - | - | - |